Acteryon is an innovative biotechnology company dedicated to the research and development of new technologies and products based on bacteriophages. Our business strategy is based on developing new therapeutics in early phases of R&D with a view to then enter into collaboration deals for pre-clinical and/or clinical development. All this is embedded in a seasoned team of professionals with extensive clinical development experience.
Our strategic goal is to become a global leader in novel natural product development, platform provision and manufacturing in the GMP standard for industrial and pharmaceutical application. Our main research areas are phages technologies development for pharmaceutical applications – prevention and treatment of bacterial infections and biofilm, as well as microbiota modulation and modern diagnostic methods. We embrace a policy of open access and knowledge exchange. We mean to become an active member of the phage community and promote biotechnological discoveries and applications.
Our Offer
Our capabilities span conceptual support in the formulation of new products to manufacturing. Our services include searching and evaluating start materials, in-house formulation development, optimization of production batches, upscaling, production, purification, testing and release of the final product.
We offer our services to research centers, universities, pharmaceutical companies and startups interested in formulation development and/or manufacturing. Our services include contractual manufacturing of entrusted materials as well as materials from large Acteryon’s deposit collection.
Our technological services include isolation and pre-selection of bacteriophages, their characterization, formulation of bacteriophage cocktail ingredients, optimization of production and purification (laboratory scale) as well as preformulation tests. For semi-technological and technological scale manufacturing, we offer optimization of production (upscaling) and purification processes (semi-technical scale), technology transfer, cataloguing and depositing of the phage, development and validation of analytical methods. The infrastructure and know-how entitle us to forge alliances in research, orders and projects with the use of aerobic, microaerophilic and anaerobic bacterial hosts. We guarantee procedure and process compliance with the requirements of GLP and GMP standards in all our work.
If you need any phage product developed, please contact us for further information.
Contact Us:
ACTERYON Sp. z o.o.
Al. Zwyciestwa 96/98, Budynek 1D/254
81-451 Gdynia, POLAND
Email: office@acteryon.com
EU Projects
National Center for Research and Development, Intelligent Development Operational Program 2014-2020, Priority axis: Support for conducting R&D works by enterprises, Measure 1.1: R&D projects for enterprises, Sub-measure 1.1.1: Industrial research and development works carried out by enterprises.
The project involves research in the area of biological and hygienic safety, the formulation of improved products and industrial implementation with application in human therapeutics and food safety. The goal is to develop and implement an antibacterial substrate that can be used in disinfection areas as a new product or a functional additive for currently used preparations. With this project, we aim to contribute to the elimination of multidrug resistant bacteria from public areas where their presence is a direct threat to patients (hospitals, clinics, healthcare centers) and consumers (food production and processing facilities).
1
Novel antibacterial protection products for use in human therapeutics and food production.
Project start date:
2019-05-01
Planned end date:
2023-12-31
Total value:
EUR 1.053,478,86
Grant value:
EUR 766.811,08
Ministry of Investment and Development, Priority axis: Support for the environment and the potential of entrepreneurs to conduct R&D activities I Measure 2.1 Support for investments in R&D infrastructure
The project involves the establishment and subsequent running of a state-of-the-art Research and Development Center complete with manufacturing suites built to GMP and GLP standards to provide the full range of services in the area of bacteriophage biotechnology from research and concept definition, through new product development, formulation, analytics, quality control, pre-clinical research, clinical testing, optimization to product manufacturing. The R&D Center will provide the necessary infrastructure for the development of innovative phage-related products and services for medical and non-medical applications. In addition to own product development, the Center will undertake contract manufacturing, providing the full set of attendant services from concept to product.
2
The Acteryon R&D Center: a one-stop-shop for own and contract research services and production in the area of bacteriophage biotechnology.
Project start date:
2019-04-30
Planned end date:
2023-12-31
Total value:
EUR 7.163.036,25
Project co-financing amount:
EUR 3.183.099,97
National Center for Research and Development, Intelligent Development Operational Program 2014-2020, Priority axis: Support for conducting R&D works by enterprises, Measure 1.1: R&D projects for enterprises, Sub-measure 1.1.1: Industrial research and development works carried out by enterprises.
The project is dedicated to the development and production of an enzyme additive to food products that successfully reduces the risks of Listeria in food products.
The implementation of the project involves the use of genetic engineering methods and tools that will enable the production of bacteriophage endolysin in the prokaryotic expression system.
The project makes the exploration of the genetic potential of bacteriophages in the field of enzymes’ antibacterial and anti-biofilm character another important area of company’s R&D linked directly to the future implementation activities
3
Phage endolysin with a broad spectrum of antibacterial activity as a modern food additive preventing infections with L. monocytogenes strains
Project start date:
2021-11-01
Planned end date:
2023-12-31
Total value:
EUR 969.334,00
Grant value:
EUR 704.852,00
National Center for Research and Development, Intelligent Development Operational Program 2014-2020, Priority axis: Support for conducting R&D works by enterprises, Measure 1.1: R&D projects for enterprises, Sub-measure 1.1.1: Industrial research and development works carried out by enterprises.
The project is dedicated to the development and production of a new bioformula associated with the support to the treatment of acne, one of the most common skin diseases.
The project refers directly to the current trends of novel treatment and study of human microbiota (skin tissue and digestive system), which has become an increasingly popular area of scientific research in recent years.
4
A new generation dermocosmetic based on bionanoparticles active against Propionibacterium acne
Project start date:
2021-07-01
Planned end date:
2023-12-31
Total value:
EUR 1.039,715,11
Project co-financing amount:
EUR 780.789,21
The Acteryon
Research and Development Center
The R&D unit will house departments responsible for phage hunt and characterization, lab testing of phage biological activities, new product development, product formulation to specific therapeutic or preventive indication and production optimization. Manufacturing facilities will be located next to the lab suits to enable production to GMP and GLP standard.
The technical and technological facilities of the Center and the constantly improved Acteryon’s know-how enable execution and implementation of projects and specialized commissioned tasks in an aerobic, microaerophilic and anaerobic environment.
We are constantly increasing our large phage collection at Acteryon – a key resource for future platforms and projects. At the end of 2021 the number of microbiologically, molecularly and bioinformatically tested and deposited in our collection number of bacteriophage strains exceeded the total of 200.
The Acteryon R&D Center is headquartered in the Maszynowa Industrial and Technological Park near Gdańsk with easy access to the national transport infrastructure and international airport.
Our team brings together extensive R&D experience and a proven track record for business excellence. It has strong competence in the area of research planning and management as well as substantial experience in commercialization, technology transfer and intellectual property management.
Our Team
Magdalena Jakubowska-Deredas
Head of R&D
Molecular biologist, experienced specialist in the field of isolation and characterization as well as metagenomic and molecular studies of environmental bacteriophages and phage enzymes; originator of technology for the production and purification of bacteriophages in accordance with the GMP standard; head of research and bioprocess technology.
Krzysztof Lemke
Product Development
Krzysztof holds a doctoral degree in medicinal chemistry and specializes in industrial biochemistry, biomaterials and nanomaterials for medical applications, specialising in biotechnological functional compositions (immunomodulatory and antibacterial formulations); owner and co-owner of many patent applications in the area of active substances and product formulations; an expert in implementation of biotechnology technologies for industrial applications.
Magdalena Furmaniak
PhD in microbiology; R&D specialist in the field of isolation, characterization and testing of bacteriophage activity; process quality control
Kinga Zglińska
A biologist, laboratory and technical specialist.
Agata Bartkowiak
Project Manager
A supervisor all administrative, formal, legal and financial procedures in the research and development and investment projects carried out by ACTERYON.
Marek Pawełczak
General management of investment and R&D projects; supervision of implementation and commercialization of projects’ results.
Contact Us:
ACTERYON Sp. z o.o.
Al. Zwyciestwa 96/98
Budynek 1D/254
81-451 Gdynia
POLAND
Email: office@acteryon.com
REGON: 368043961
NIP: 9562326786
KRS: 0000691393